Uliledlimab |
TJ-4309; TJ-004309; TJD-5 |
Phase 3 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis |
Details
|
Oleclumab |
MEDI-9447 |
Phase 3 Clinical |
Medimmune Llc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Hemangiosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Liposarcoma; Prostatic Neoplasms; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
Dalutrafusp alfa |
GS-1423; AGEN-1423 |
Phase 2 Clinical |
Agenus Inc |
Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Interferon beta-1a (Faron Pharmaceuticals) |
MR-11A8; FP-1201; FP-1201-lyo |
Phase 2 Clinical |
Faron Pharmaceuticals Ltd |
Multiple Organ Failure; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Acute Lung Injury |
Details
|
BMS-986179 |
BMS-986179 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Solid tumours |
Details
|
Mupadolimab |
CPX-006; COR-004 (Corvus Pharmaceuticals); CPI-006 |
Phase 2 Clinical |
Corvus Pharmaceuticals Inc |
Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms |
Details
|
Quemliclustat |
AB-680 |
Phase 2 Clinical |
Arcus Biosciences Inc |
Biliary Tract Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Dresbuxelimab |
AK-119 |
Phase 2 Clinical |
Akeso Pharmaceuticals Inc |
Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
S-095024 |
S-095024; S095024 |
Phase 2 Clinical |
Institut De Recherches Internationales Servier, Servier Bio-Innovation LLC |
Carcinoma, Non-Small-Cell Lung |
Details
|
HB-0045 |
HB-0045; HB0045 |
Phase 2 Clinical |
Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
JAB-BX102 |
JAB-BX102 |
Phase 2 Clinical |
Jacobio Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
LY-3475070 |
LY-3475070 |
Phase 1 Clinical |
Eli Lilly And Company |
Neoplasms |
Details
|
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) |
|
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Uprevstobart |
INCA-00186 |
Phase 1 Clinical |
Incyte Corp Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Neoplasms |
Details
|
HB-0052 |
HB-0052; HB0052 |
Phase 1 Clinical |
Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
BPI-472372 |
BPI-472372 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
BB-1709 |
BB-1709 |
Phase 1 Clinical |
Bliss Biopharmaceutical (Hangzhou) Co Ltd |
Solid tumours |
Details
|
PM-1015 |
PM1015; PM-1015 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
AK-131 |
AK-131 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
PT-199 |
PT-199 |
Phase 1 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
IBI-325 |
IBI-325 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
BR-101 |
BR101; BR-101 |
Phase 1 Clinical |
BioRay Pharmaceutical Co Ltd |
Solid tumours |
Details
|
CB-708 |
CB-708; CB708; ATG-037 |
Phase 1 Clinical |
Calithera Biosciences Inc |
Solid tumours; Neoplasms |
Details
|
HLX-23 |
HLX-23 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Lymphoma |
Details
|
ORIC533 |
ORIC-533 |
Phase 1 Clinical |
Oric Pharmaceuticals Inc |
Multiple Myeloma; Neoplasm Metastasis |
Details
|
IPH-5301 |
IPH-5301 |
Phase 1 Clinical |
Innate Pharma |
Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis |
Details
|
HBM-1007 |
HBM1007; R 1007; HBM 1007; HBM-1007 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms |
Details
|
ABSK-051 |
ABSK051 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours; Neoplasms |
Details
|
Uliledlimab |
TJ-4309; TJ-004309; TJD-5 |
Phase 3 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis |
Details
|
Oleclumab |
MEDI-9447 |
Phase 3 Clinical |
Medimmune Llc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Hemangiosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Liposarcoma; Prostatic Neoplasms; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
Dalutrafusp alfa |
GS-1423; AGEN-1423 |
Phase 2 Clinical |
Agenus Inc |
Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Interferon beta-1a (Faron Pharmaceuticals) |
MR-11A8; FP-1201; FP-1201-lyo |
Phase 2 Clinical |
Faron Pharmaceuticals Ltd |
Multiple Organ Failure; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Acute Lung Injury |
Details
|
BMS-986179 |
BMS-986179 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Solid tumours |
Details
|
Mupadolimab |
CPX-006; COR-004 (Corvus Pharmaceuticals); CPI-006 |
Phase 2 Clinical |
Corvus Pharmaceuticals Inc |
Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms |
Details
|
Quemliclustat |
AB-680 |
Phase 2 Clinical |
Arcus Biosciences Inc |
Biliary Tract Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Dresbuxelimab |
AK-119 |
Phase 2 Clinical |
Akeso Pharmaceuticals Inc |
Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
S-095024 |
S-095024; S095024 |
Phase 2 Clinical |
Institut De Recherches Internationales Servier, Servier Bio-Innovation LLC |
Carcinoma, Non-Small-Cell Lung |
Details
|
HB-0045 |
HB-0045; HB0045 |
Phase 2 Clinical |
Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
JAB-BX102 |
JAB-BX102 |
Phase 2 Clinical |
Jacobio Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
LY-3475070 |
LY-3475070 |
Phase 1 Clinical |
Eli Lilly And Company |
Neoplasms |
Details
|
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) |
|
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Uprevstobart |
INCA-00186 |
Phase 1 Clinical |
Incyte Corp Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Neoplasms |
Details
|
HB-0052 |
HB-0052; HB0052 |
Phase 1 Clinical |
Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
BPI-472372 |
BPI-472372 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
BB-1709 |
BB-1709 |
Phase 1 Clinical |
Bliss Biopharmaceutical (Hangzhou) Co Ltd |
Solid tumours |
Details
|
PM-1015 |
PM1015; PM-1015 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
AK-131 |
AK-131 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
PT-199 |
PT-199 |
Phase 1 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
IBI-325 |
IBI-325 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
BR-101 |
BR101; BR-101 |
Phase 1 Clinical |
BioRay Pharmaceutical Co Ltd |
Solid tumours |
Details
|
CB-708 |
CB-708; CB708; ATG-037 |
Phase 1 Clinical |
Calithera Biosciences Inc |
Solid tumours; Neoplasms |
Details
|
HLX-23 |
HLX-23 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Lymphoma |
Details
|
ORIC533 |
ORIC-533 |
Phase 1 Clinical |
Oric Pharmaceuticals Inc |
Multiple Myeloma; Neoplasm Metastasis |
Details
|
IPH-5301 |
IPH-5301 |
Phase 1 Clinical |
Innate Pharma |
Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis |
Details
|
HBM-1007 |
HBM1007; R 1007; HBM 1007; HBM-1007 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms |
Details
|
ABSK-051 |
ABSK051 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours; Neoplasms |
Details
|